Lyell Working Capital from 2010 to 2025
| LYEL Stock | USD 0.70 0.04 6.06% |
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
Lyell |
About Lyell Immunopharma Financial Statements
Lyell Immunopharma investors utilize fundamental indicators, such as Working Capital, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lyell Immunopharma Correlation against competitors. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.